Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of multiple doses of LC28-0126 in healthy male subjects
NCT03196804Phase 1Completed
- Sponsor
- LG Chem
- Start
- Jun 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute myocardial infarction (AMI), graft-versus-host disease (GVHD) and oral mucositis (OM) comparing LC28-0126 with Placebo (2 arms). Primary endpoint: Adverse events at 18 days. Started Jun 2017; status: completed.
02
Drugs
LC28-0126
03
Conditions
acute myocardial infarction (AMI)graft-versus-host disease (GVHD)oral mucositis (OM)
Beyond the preview
Go deeper on NCT03196804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196804.